Covalon Recieves European Patent for Drug Delivery Method Using Liposomes Within Therapeutic Collagen-Based Hydrogels.MISSISSAUGA, Ontario For the First Nation, see . Mississauga (pronounced: [ˌmɪsɪˈsɑgə] listen -- Covalon Technologies Ltd. (Covalon) (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:COV COV Composés Organiques Volatiles (French) COV Compuestos Orgánicos Volátiles (Spanish: Volatile Organic Compounds) COV Coefficient of Variation COV City of Villians (game) ) is extremely pleased to announce that it has received European Patent protection for drug delivery technology concerning using liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. within collagen-based hydrogel hy·dro·gel n. A colloidal gel in which the particles are dispersed in water. hydrogel a gel that contains water. hydrogel Wound care A polymer absorptive wound dressing. See Dressing. . The technology can be used as a drug delivery platform involving the retention of a drug within liposomes which are microscopic spheres of lipid designed to act as time-release drug depots.The patent augments Covalon's technology position in the expanding area of convergent medical devices. The medical devices that may benefit form the technology include wound dressings, implantable medical devices and wound closure systems useful for helping to reduce hospital acquired infection. The type of therapeutic agent that can be encapsulated within the liposomes is not restricted to a single type of antiseptic or combination of one or more of these. The hydrogel composition might comprise a variety of active agents and include antibiotics, hormones, growth factors and other factors that are beneficial for the medical condition under management. Covalon Technologies Ltd. is an advanced medical biosystems company that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry Polymer chemistry or macromolecular chemistry is a multidisciplinary science that deals with the chemical synthesis and chemical properties of polymers or macromolecules. and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. , and microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. attachment. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release. This document contains forward-looking statements. These statements relate to future events or future performance. In some cases, forward-looking statements can be identified by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of any of these terms or comparable terminology. Such statements reflect the current views of management of the Company with respect to future events. Actual events or results may differ materially. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any any obligation to up0date any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments Covalon Technologies Ltd. (TSX VENTURE:COV) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion